PC
SCMP

Palo Capital’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Palo Capital’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-17,351
Closed -$190K – 254
2016
Q1 		$190K Buy
+17,351
New +$219K 0.15% 152

Other funds holding SCMP

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Palo Capital's SCMP Position: Q2 2016 in Review

Palo Capital sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q2 2016, closing a stake of 17,351 shares — an estimated $190K sold.

Palo Capital first reported a position in SCMP in Q1 2016 and held it in 1 quarter. The position peaked at $190K in Q1 2016. 136 funds tracked by Wall St. Rank hold SCMP as of Q2 2016.

  • Palo Capital reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Palo Capital sold 17,351 Sucampo Pharmaceuticals, Inc. shares in Q2 2016, an estimated $190K.
  • Palo Capital first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
  • Palo Capital's Sucampo Pharmaceuticals, Inc. position peaked at $190K in Q1 2016.
  • 136 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q2 2016.

Based on Palo Capital's 13F filing for Q2 2016, filed 20 Jul 2016.